Survival from 9 months of age among HIV-infected and uninfected Zambian children prior to the availability of antiretroviral therapy

Catherine Sutcliffe, Susana Scott, Nanthalile Mugala, Zaza Ndhlovu, Mwaka Monze, Thomas C Quinn, Simon Cousens, Diane Griffin, William J Moss

Research output: Contribution to journalArticle

Abstract

Background. Few prospective studies have measured survival rates among human immunodeficiency virus (HIV)-infected children in sub-Saharan Africa prior to the availability of antiretroviral therapy. Methods. In the context of an observational study of the immunogenicity of measles vaccine in Zambia, we prospectively followed up children from approximately 9 months of age and assessed survival rates, risk factors for mortality, and circumstances at the time of death according to HIV-infection or HIV-exposure status. Results. There were 56 deaths among 492 study children during follow-up to 3 years of age. Thirty-nine percent of the 105 children with HIV infection died during the study period, compared with 5.0% of the 260 HIV-seropositive but uninfected children and 1.6% of the 127 HIV-seronegative children. Estimated survival probabilities from 9 through 36 months of age were 52% among HIV-infected children, 95% among initially HIV-seropositive but uninfected children, and 98% among HIV-seronegative children. In multivariable analyses, history of a clinic visit within the 4 weeks prior to study entry (adjusted hazard ratio, 4.6; 95% confidence interval, 1.5-13.5), hemoglobin level + T lymphocyte percentage

Original languageEnglish (US)
Pages (from-to)837-844
Number of pages8
JournalClinical Infectious Diseases
Volume47
Issue number6
DOIs
StatePublished - Sep 15 2008

Fingerprint

HIV
Therapeutics
Virus Diseases
Survival Rate
Measles Vaccine
Zambia
Africa South of the Sahara
Ambulatory Care
Observational Studies
Hemoglobins
Prospective Studies
Confidence Intervals
T-Lymphocytes
Mortality

ASJC Scopus subject areas

  • Immunology

Cite this

Survival from 9 months of age among HIV-infected and uninfected Zambian children prior to the availability of antiretroviral therapy. / Sutcliffe, Catherine; Scott, Susana; Mugala, Nanthalile; Ndhlovu, Zaza; Monze, Mwaka; Quinn, Thomas C; Cousens, Simon; Griffin, Diane; Moss, William J.

In: Clinical Infectious Diseases, Vol. 47, No. 6, 15.09.2008, p. 837-844.

Research output: Contribution to journalArticle

@article{9b3709aad9f444eb89f10fa00d0c8fd9,
title = "Survival from 9 months of age among HIV-infected and uninfected Zambian children prior to the availability of antiretroviral therapy",
abstract = "Background. Few prospective studies have measured survival rates among human immunodeficiency virus (HIV)-infected children in sub-Saharan Africa prior to the availability of antiretroviral therapy. Methods. In the context of an observational study of the immunogenicity of measles vaccine in Zambia, we prospectively followed up children from approximately 9 months of age and assessed survival rates, risk factors for mortality, and circumstances at the time of death according to HIV-infection or HIV-exposure status. Results. There were 56 deaths among 492 study children during follow-up to 3 years of age. Thirty-nine percent of the 105 children with HIV infection died during the study period, compared with 5.0{\%} of the 260 HIV-seropositive but uninfected children and 1.6{\%} of the 127 HIV-seronegative children. Estimated survival probabilities from 9 through 36 months of age were 52{\%} among HIV-infected children, 95{\%} among initially HIV-seropositive but uninfected children, and 98{\%} among HIV-seronegative children. In multivariable analyses, history of a clinic visit within the 4 weeks prior to study entry (adjusted hazard ratio, 4.6; 95{\%} confidence interval, 1.5-13.5), hemoglobin level + T lymphocyte percentage",
author = "Catherine Sutcliffe and Susana Scott and Nanthalile Mugala and Zaza Ndhlovu and Mwaka Monze and Quinn, {Thomas C} and Simon Cousens and Diane Griffin and Moss, {William J}",
year = "2008",
month = "9",
day = "15",
doi = "10.1086/591203",
language = "English (US)",
volume = "47",
pages = "837--844",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - Survival from 9 months of age among HIV-infected and uninfected Zambian children prior to the availability of antiretroviral therapy

AU - Sutcliffe, Catherine

AU - Scott, Susana

AU - Mugala, Nanthalile

AU - Ndhlovu, Zaza

AU - Monze, Mwaka

AU - Quinn, Thomas C

AU - Cousens, Simon

AU - Griffin, Diane

AU - Moss, William J

PY - 2008/9/15

Y1 - 2008/9/15

N2 - Background. Few prospective studies have measured survival rates among human immunodeficiency virus (HIV)-infected children in sub-Saharan Africa prior to the availability of antiretroviral therapy. Methods. In the context of an observational study of the immunogenicity of measles vaccine in Zambia, we prospectively followed up children from approximately 9 months of age and assessed survival rates, risk factors for mortality, and circumstances at the time of death according to HIV-infection or HIV-exposure status. Results. There were 56 deaths among 492 study children during follow-up to 3 years of age. Thirty-nine percent of the 105 children with HIV infection died during the study period, compared with 5.0% of the 260 HIV-seropositive but uninfected children and 1.6% of the 127 HIV-seronegative children. Estimated survival probabilities from 9 through 36 months of age were 52% among HIV-infected children, 95% among initially HIV-seropositive but uninfected children, and 98% among HIV-seronegative children. In multivariable analyses, history of a clinic visit within the 4 weeks prior to study entry (adjusted hazard ratio, 4.6; 95% confidence interval, 1.5-13.5), hemoglobin level + T lymphocyte percentage

AB - Background. Few prospective studies have measured survival rates among human immunodeficiency virus (HIV)-infected children in sub-Saharan Africa prior to the availability of antiretroviral therapy. Methods. In the context of an observational study of the immunogenicity of measles vaccine in Zambia, we prospectively followed up children from approximately 9 months of age and assessed survival rates, risk factors for mortality, and circumstances at the time of death according to HIV-infection or HIV-exposure status. Results. There were 56 deaths among 492 study children during follow-up to 3 years of age. Thirty-nine percent of the 105 children with HIV infection died during the study period, compared with 5.0% of the 260 HIV-seropositive but uninfected children and 1.6% of the 127 HIV-seronegative children. Estimated survival probabilities from 9 through 36 months of age were 52% among HIV-infected children, 95% among initially HIV-seropositive but uninfected children, and 98% among HIV-seronegative children. In multivariable analyses, history of a clinic visit within the 4 weeks prior to study entry (adjusted hazard ratio, 4.6; 95% confidence interval, 1.5-13.5), hemoglobin level + T lymphocyte percentage

UR - http://www.scopus.com/inward/record.url?scp=51549103259&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=51549103259&partnerID=8YFLogxK

U2 - 10.1086/591203

DO - 10.1086/591203

M3 - Article

C2 - 18680417

AN - SCOPUS:51549103259

VL - 47

SP - 837

EP - 844

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 6

ER -